Sotradecol™
Sodium Tetradecyl Sulfate Injection

Sotradecol™ (sodium tetradecyl sulfate injection) is a sterile, non-pyrogenic sclerosing agent that has recently been approved by the FDA. Sotradecol™ is one of a range of sterile, injectable prescription products manufactured by Bioniche Pharma Group Limited. Now distributed by AngioDynamics®, Inc., Sotradecol is for intravenous use only, and is available in two strengths: 1% and 3%, packaged in boxes of five 2 ml vials.

For further information on Sotradecol™, including its approved indication and possible side effects, please visit www.sotradecolusa.com.

• Now Approved by the FDA
  FDA approved Sotradecol™ by Bioniche Pharma is now available in the US market.
• Well-Known Molecule in the US Sclerotherapy Market
  Sodium Tetradecyl Sulfate is a well-known molecule in the US sclerotherapy Market.
• Manufactured in an FDA cGMP Approved Sterile Facility
  Sotradecol™ is now manufactured by Bioniche Pharma Group Limited that produces both brand name and specialty sterile injectable products for world markets. Products are manufactured in an IMB (Europe), FDA and Health Canada approved cGMP and ISO 13485 compliant facility, guaranteeing high standards of final “sodium tetradecyl sulfate injection” formulation and complying with all public safety guidelines.
• The Only Commercially Available “Sodium Tetradecyl Sulfate Injection” in the US Market
  Sotradecol™ is now available through AngioDynamics®, Inc. for use in both sclerotherapy clinics and hospitals.
• Available in Two Strengths; 1% and 3%, in 2 ml Vials
  Sotradecol™ is available in two strengths, a 1% and 3%, in 2ml vials.
  
• Intravenous Injection in New 5 Vial Packs
  Sotradecol™ is now available in packs of 5 vials to better service patients requiring a longer or more extensive course of treatment.